135 related articles for article (PubMed ID: 11313970)
1. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Jang JJ; Han JY; Lee JY; Yoo NJ
Cancer Res; 1999 Nov; 59(22):5683-6. PubMed ID: 10582684
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
4. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity.
Adams J; Cuthbert-Heavens D; Bass S; Knowles MA
Cancer Lett; 2005 Apr; 220(2):137-44. PubMed ID: 15766588
[TBL] [Abstract][Full Text] [Related]
5. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
6. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
7. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
Wu WG; Soria JC; Wang L; Kemp BL; Mao L
Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
[TBL] [Abstract][Full Text] [Related]
8. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
[TBL] [Abstract][Full Text] [Related]
10. A study of TRAIL receptors in squamous cell carcinoma of the head and neck.
Teng MS; Brandwein-Gensler MS; Teixeira MS; Martignetti JA; Duffey DC
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):407-12. PubMed ID: 15897419
[TBL] [Abstract][Full Text] [Related]
11. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
14. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.
Shin MS; Kim HS; Lee SH; Park WS; Kim SY; Park JY; Lee JH; Lee SK; Lee SN; Jung SS; Han JY; Kim H; Lee JY; Yoo NJ
Cancer Res; 2001 Jul; 61(13):4942-6. PubMed ID: 11431320
[TBL] [Abstract][Full Text] [Related]
15. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
Rubio-Moscardo F; Blesa D; Mestre C; Siebert R; Balasas T; Benito A; Rosenwald A; Climent J; Martinez JI; Schilhabel M; Karran EL; Gesk S; Esteller M; deLeeuw R; Staudt LM; Fernandez-Luna JL; Pinkel D; Dyer MJ; Martinez-Climent JA
Blood; 2005 Nov; 106(9):3214-22. PubMed ID: 16051735
[TBL] [Abstract][Full Text] [Related]
16. Rare loss-of-function mutation of a death receptor gene in head and neck cancer.
Pai SI; Wu GS; Ozören N; Wu L; Jen J; Sidransky D; El-Deiry WS
Cancer Res; 1998 Aug; 58(16):3513-8. PubMed ID: 9721851
[TBL] [Abstract][Full Text] [Related]
17. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis and mRNA expression of trail-receptors in human breast cancer.
Seitz S; Wassmuth P; Fischer J; Nothnagel A; Jandrig B; Schlag PM; Scherneck S
Int J Cancer; 2002 Nov; 102(2):117-28. PubMed ID: 12385006
[TBL] [Abstract][Full Text] [Related]
19. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
